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 Implication for health policy/practice/research/medical edu-
cation:
Hepatitis E is a significant health concern in endemic area. 
During graft transplantation it can affect the recovery process 
and may increase chronicity. This study is recommended to 
the internal and infectious specialists, graft transplantation 
surgeons and virologists.
Sepehrvand  et al. demonstrated a considerable 
seroprevalence  rate  of  anti-HEV  in  Iranian  kidney 
transplant recipients (1). The impact of HEV infection 
on  renal  transplantation  and  the  risk  of  chronic  HEV 
infection in this group are debated—issues that I 
would like to discuss. Hepatitis E virus (HEV) was first 
discovered in New Delhi, India, in 1955 (2). The virus is 
transmitted via the oral-fecal route (3). Other possible 
routes of transmission include blood transfusions, 
drug vertical transmission, person-to-person contact, 
and zoonotic transmission (4, 5). The frequency of HEV 
transmission by non-fecal-oral routes remains unknown 
(2, 6). In endemic areas, exposure occurs in childhood (7, 
8). In high-income countries, most cases of hepatitis E 
appear to be acquired locally and are not imported from 
endemic regions. In these areas, it likely has a zoonotic 
origin (9). In immunocompetent individuals, hepatitis E 
is a self-limited disease. However, HEV can cause chronic 
infection in solid organ transplants (10, 11), patients who 
receive chemotherapy (12), and HIV-infected persons 
(13). HEV infection causes chronic hepatitis in more than 
60% of recipients of solid organ transplants. Factors 
that increase the risk of chronic hepatitis in solid organ 
transplant recipients are shorter interval since the 
transplant,  lower  levels  of  liver  enzymes  and  serum 
creatinine, lower platelet counts, and tacrolimus-based 
immunosuppression  (compared  with  cyclosporin  A), 
the most significant of which are tacrolimus use and low 
platelet count (11, 14, 15).
In  otherwise  healthy  kidney  transplant  recipients, 
HEV might be considered the etiological agent for the 
development of hepatitis in those who live in endemic 
regions (16). Viral hepatitis E may progress rapidly to 
cirrhosis in renal transplant recipients (17). Although 
occult infection of HEV may be transferred to the recipient 
via liver graft (18), other allograft organs appear to be clear 
for transmission of the virus. As a result, screening for HEV 
at the time of transplantation is only recommended in 
liver transplant donors and recipients in endemic areas 
(19). Such a screen is not recommended for patients with 
renal failure who are waiting for renal transplantation. 
Rising liver enzyme levels is a nonspecific finding 
following solid organ transplantation. Renal transplant 
patients may experience such increases, due primarily 
to drug reactions, sepsis, and hepatotropic virus-related 
infectious diseases. The diagnosis of viral hepatitis E in 
renal transplant recipients is usually made by ELISA. In 
renal transplant recipients, the seroprevalence of anti-Hepat Mon. 2011;11(8):599-600
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HEV IgG is 6% to 16% (10). Other immunocompromised 
hosts, such as patients with hematological malignancies, 
might  avoid  forming  HEV  IgG  following  an  infection. 
Moreover, viremia may exist for more than 6 months after 
an acute infection (20). In addition, the development of 
HEV IgG in renal transplant patients does not appear to 
be universal. The presentation of chronic hepatitis in 
renal transplant patients may be associated with normal 
liver enzymes and a negative serological assay (21). 
This phenomenon underscores the need for molecular 
studies in suspected subjects.
Decreasing the numbers and doses of 
immunosuppressive drugs remains the first approach 
toward controlling viral hepatitis E in renal transplant 
recipients.  A  prolonged  follow-up  period  might  be 
required to assess the eventual outcome (14). In addition, 
pegylated interferon alpha-2b may be useful in the 
management of chronic HEV infections in solid organ 
recipients in whom a reduction of the immunosuppressive 
regimen  is  insufficient  (22).  Interestingly,  3-month 
Peg-  IFN-α-2a  therapy  was  shown  to  be  efficacious  in 
a  hemodialysis  patient  with  chronic  HEV  infection 
following renal transplantation (23). In 2010, the efficacy 
of ribavirin 12 mg/kg of body weight daily for 12 weeks 
was reported in kidney transplant patients with chronic 
HEV infection. However, due to the short term follow-up 
(3 months), eradication of the virus could not be claimed 
(24). In 2011, another report demonstrated that a 3-month 
course  of  oral  ribavirin  (17  mg/kg/day)  in  solid  organ 
transplant patients with chronic HEV infection induced 
a sustained virological response for more than 4 months 
after cessation of ribavirin (25). A long follow-up is always 
required to evaluate the outcome of HEV infection in 
solid organ transplant patients. HEV infection may cause 
cirrhosis in renal transplant individuals. As a result, close 
follow-up  is  required  after  the  diagnosis.  In  addition, 
HEV infection may result in nonhepatic complications 
in  kidney  transplant  recipients.  Neurological  diseases 
that affect the peripheral or central nervous system have 
been  demonstrated  in  renal  transplants  with  chronic 
HEV infection. Surprisingly, HEV was isolated from the 
cerebrospinal fluid in such patients (26).
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